GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nilofabicin   Click here for help

GtoPdb Ligand ID: 10984

Synonyms: CG-400549 | CG400549
PDB Ligand
Compound class: Synthetic organic
Comment: Nilofabicin is an antibacterial compound that functions by inhibiting bacterial enoyl-ACP reductase (FabI) [2]. It has no activity against Gram-positive bacteria.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 85.49
Molecular weight 340.12
XLogP 3.22
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1cccc(c1C)Cn1ccc(cc1=O)OCCc1cccs1
Isomeric SMILES Nc1cccc(c1C)Cn1ccc(cc1=O)OCCc1cccs1
InChI InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
InChI Key YCLREGRRHGLOAK-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Nilofabicin has completed a Phase 2 clinical study (NCT01593761) to assess efficacy in subjects with acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01593761 Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus Phase 2 Interventional CrystalGenomics, Inc.